Molecular Devices Acquires Cellesce Ltd
December 6, 2022
Molecular Devices, a life-science instrumentation company, has acquired Cellesce Ltd, a Cardiff-based developer and manufacturer of patient-derived organoids (PDOs) for large-scale drug screening. The deal expands Molecular Devices' 3D biology capabilities and combines Cellesce's industrial-scale PDO production with Molecular Devices' automated organoid screening platforms to accelerate adoption of physiologically relevant cell models in drug discovery.
- Buyers
- Molecular Devices, LLC
- Targets
- Cellesce Ltd
- Industry
- Biotechnology
- Location
- Wales, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Bio-Rad Acquires Celsee, Inc.
April 9, 2020
Biotechnology
Bio-Rad Laboratories has acquired Celsee, Inc., a developer of instruments and consumables for single-cell isolation, detection and analysis. The acquisition expands Bio‑Rad’s capabilities in single-cell analysis and precision medicine; terms were not disclosed.
-
Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities
July 11, 2023
Biotechnology
Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.
-
ARCHIMED Acquires Majority Stake in Cellese
April 9, 2024
Consumer Products
Global healthcare private equity firm ARCHIMED has acquired a majority stake in Cellese, the Irvine, California–based developer of growth factor- and exosome-based dermo-cosmetic products sold under the AnteAGE brand. ARCHIMED will support Cellese's commercialization and international expansion while founder Ian Sanderson and his family roll a meaningful portion of proceeds into a minority stake.
-
ICON plc Acquires MolecularMD Corporation
February 21, 2019
Healthcare Services
ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
-
Impact BioMedical Acquires Celios
February 26, 2025
Manufacturing
Impact BioMedical Inc. (NYSE American: IBO) acquired Celios, an air purification technology company, in an all‑equity transaction valued at approximately $1.15 million. The acquisition adds Celios' patented, U.S.-manufactured filtration technology (patents through 2043) to Impact BioMedical's roll‑up strategy to expand its healthcare and wellness product portfolio and generate immediate revenue.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.